Clinical trials: sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cancer
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02752516
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT03019276
- Testing
- TQ-B3101
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics
A study of TQ-B3139, inhibitor of ALK/C-Met tyrosine kinase, in patient with advanced cancer
- Trial name
- NCT03099330
- Testing
- TQ-B3139
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Soft Tissue Sarcoma
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.
- Trial name
- NCT02449343
- Testing
- Anlotinib
- Where
- 25 sites in China
- Volunteers
- 233 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2.
- Trial name
- NCT02029209
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hemophilia A
Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy in adult and adolescent (12-65 years)…
- Trial name
- NCT02930317
- Testing
- Recombinant Factor VIII (50 IU/kg), Recombinant Factor VIII (On-demand treatment)
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Drug-Induced Liver Injury
Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury
The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.
- Trial name
- NCT02734966
- Testing
- Magnesium Isoglycyrrhizinate Injection 100mg OD, Magnesium Isoglycyrrhizinate Injection 200mg OD, Tiopronin Injection
- Where
- 8 sites in China
- Volunteers
- 174 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
- Trial name
- ALTER0802 (NCT02809534)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anlotinib, RCC
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072031
- Testing
- Anlotinib, Sunitinib maleate
- Where
- 15 sites in China
- Volunteers
- 133 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN (NCT01833923)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT01924195
- Testing
- Anlotinib
- Where
- 13 sites in China
- Volunteers
- 117 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Opioid-induced Constipation
Study of Methylnaltrexone in Opioid-Induced Constipation Patients
This is a multicenter, randomized, double-blind , placebo-controlled trail to investigate the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.
- Trial name
- NCT02574819
- Testing
- Methylnaltrexone (MNTX)
- Where
- 12 sites in China
- Volunteers
- 198 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
A Study of Sinotecean on Tolerance and Pharmacokinetics
This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.
- Trial name
- NCT02469883
- Testing
- Sinotecean
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Myeloid Leukemia
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
1. purpose: To conduct the relative bioavailability study of a single dose and multiple doses of imatinib mesylate capsule (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus Glivec (Novartis Pharma Stein AG). 2.
- Trial name
- NCT01795716
- Testing
- mesylate imatinib capsule, Glivec
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bleeding Gastric Ulcer, Bleeding Duodenal Ulcer
Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding
The purpose of this study is to evaluate the safety and Efficacy of L- Pantoprazole sodium to treat upper gastrointestinal ulcer bleeding.
- Trial name
- NCT02108756
- Testing
- L-pantoprazole sodium, Panmeilu
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hospital-acquired Pneumonia
Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults
1. To evaluate the clinical and microbiological efficacy and safety of Colistimethate sodium Injection Vial to treat adults with hospital-acquired pneumonia . 2.
- Trial name
- NCT01940731
- Testing
- Colistimethate sodium
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Community Acquired Pneumonia
A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects
- Trial name
- NCT01937832
- Testing
- Faropenem, Ertapenem
- Where
- 7 sites in China
- Volunteers
- 540 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Community Acquired Pneumonia
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
- Trial name
- NCT01886053
- Testing
- Faropenem（high dose group）, Faropenem（low-dose group), Ertapenem
- Where
- 9 sites in China
- Volunteers
- 189 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor
A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
1. purpose: to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study 2. Experimental Design： A phase Ⅰ study of single-center 3.
- Trial name
- NCT01806376
- Testing
- Subutinib Maleate capsules
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.